Immunic has reported positive new data from a phase 2 trial of vidofludimus calcium (IMU-838) to treat relapsing-remitting multiple sclerosis (RRMS). The treatment helped to lower the rate of ...

The US government has announced the ten drugs selected for the first round of pricing negotiations under President Biden’s Inflation Reduction Act (IRA). The IRA allows Medicare, the government health ...

The vaccine, Ad26.COV2.S, induced a robust immune response in monkeys, demonstrated by high levels of neutralising antibodies. According to J&J, this immune response successfully prevented subsequent ...

The US health department has proposed three new models to help lower the cost of drugs, promote accessibility and improve quality of care for those enrolled in voluntary government health insurance ...

World Hepatitis Day takes place today, with this year’s theme, ‘I can’t wait’, highlighting the need to accelerate the fight against viral hepatitis to reach the 2030 elimination target.

As technology advances there is a growing array of MedTech solutions – wearables, voice-activated devices, telehealth, etc. – to better support patients in their daily lives. However, MedTech research ...

AstraZeneca (AZ) and Merck’s – known as MSD outside the US and Canada – Lynparza (olaparib) has been recommended by the National Institute for Health and Care Excellence (NICE) as part of a ...

Amgen has successfully completed its previously announced acquisition of ChemoCentryx in an agreement valued at approximately $3.7bn in cash. ChemoCentryx is a biopharmaceutical company focused on ...

Gilead and EVOQ Therapeutics (EVOQ) have entered into a collaboration and licensing agreement aimed at advancing immunotherapies for the treatment of rheumatoid arthritis (RA) and lupus. Under the ...

German company Merck KGaA has signed an exclusive licence agreement with Swiss biopharma company Debiopharm for its late-stage oncology asset xevinapant. Xevinapant is a potentially first-in-class ...

A group of scientists from the University of Surrey have shared findings from a seven-year research study, revealing that a new approach could be on the horizon for treating one of the most prevalent ...

Merck & Co – known as MSD outside the US and Canada – and Moderna have announced positive phase 2b trial results investigating the use of their personalised mRNA cancer vaccine, mRNA-4157/V940, in ...